[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurologic-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurologic-disorder":35},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,57,93,129,151,174,196,221,247,274,309,346,376,401,425,447,470,493,519,546,568,587,608,634,656],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":38,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100472474","rett-syndrome-registry-100472474",false,"NCT05432349","Rett Syndrome Registry","Rett Syndrome Real World Data Observational Registry","RSR","Inclusion Criteria:\n\n* Male or female with a pathologic loss of function alteration of MECP2\n\nExclusion Criteria:\n\n* Male or female with a gain of function alteration of MECP2, including those with MEPC2 duplication or triplication","ALL","0 Years","99 Years",{"count":22,"type":23},3000,"ESTIMATED","5 Years","OBSERVATIONAL","The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for Rett syndrome.",[28,29,30,31,32,33,34,35,36,37],"Rett Syndrome","Rett Syndrome, Atypical","Genetic Disease","Genetic Diseases, X-Linked","Intellectual Disability","Neurobehavioral Manifestations","Neurologic Manifestations","Neurologic Disorder","Neurodevelopmental Disorders","Nervous System Diseases",[39,40,41,42,43],"Rett syndrome","MECP2","Neurodevelopmental disorder","Registry","Natural History Study","RECRUITING","2026-06-26",{"date":47,"type":48},"2026-06-30","ACTUAL",{"date":50,"type":48},"2022-08-02",{"date":52,"type":23},"2028-07",{"name":54,"class":55},"International Rett Syndrome Foundation","OTHER",19,{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100563531","combined-whole-brain-structural-and-functional-mri-for-the-prediction-of-neurological-recovery-after-cardiac-arrest-100563531","NCT06617377","Combined Whole-brain Structural and Functional MRI for the Prediction of Neurological Recovery After Cardiac Arrest","Use of Brain Structural and Functional Connectomes for the Prediction of Neurological Recovery in Coma Patients After Cardiac Arrest","ARISE","Inclusion Criteria:\n\n* Adult patients (male or female ≥ 18 years).\n* Coma, as indicated by a Glasgow Coma Scale (GCS) ≤ 8 (motor score ≤ 2) immediately after CA resuscitation and before sedation onset.\n* Persisting unconsciousness, defined as the inability to obey verbal commands, after at least 72 hours from complete withdrawal of sedation in normothermia conditions.\n* Written informed consent from patient's legal representative.\n* Affiliation or beneficiary to the French social security system.\n\nExclusion Criteria:\n\n* Brain death.\n* Coma explained by other cause than CA.\n* Likely poor neurological outcome based on early predictors, following ERC-ESCIM 2021 recommendations. In a comatose patient with GCS motor score ≤ 3 at ≥ 72 h from ROSC, in the absence of confounders, the identification of at least two of the following: bilaterally absent pupillary light and corneal reflexes at ≥ 72h, bilaterally absent N20 SSEP ≥ 24h; neuron-specific enolase (NSE) \\> 60 μg\u002Fl at 48h and\u002For 72h, status myoclonus ≤72h.\n* Decision of WLST previous to patient recruitment, based on early predictors of poor neurological outcome, age, co-morbidity, general organ function and patient's preferences.\n* Life expectancy shorter than 6 months based on pre-morbid conditions.\n* Former neurological functional disability (mRS \\> 2 before CA).\n* MRI contraindication: medical material not MRI compatible, claustrophobia\n* Known hypersensitivity to gadoteric acid, meglumin or any drug containing gadolinium\n* Severe kidney failure defined as a KDIGO score \\> 3 (glomerular filtration rate \\\u003C 30 ml\u002Fmin\u002F1.73 m2 or renal replacement therapy).\n* Hemodynamic shock or severe respiratory failure precluding patient's transport and MRI scanning.\n* Pregnancy or nursing woman.\n* Patient under juridical protection.","18 Years",{"count":67,"type":23},263,"INTERVENTIONAL",[70],"NA","To assess the performance of a predictive model resulting from the analysis of sMRI\u002FfMRI\u002Fcontrast-enhanced MRI-derived personalized connectomic data, as compared with standard predictors (clinical examination, electrophysiology, serum biomarker, standard neuroimaging) collected ≥ 72h from sedation withdrawal and in normothermia condition, to predict anoxoischemic coma neurological outcome at 6 months.",[73,74,75,35],"Coma","Cardiac Arrest","Disorder of Consciousness",[77,78,79,80,81,82],"prognosis","coma","cardiac arrest","Structural MRI","resting-state","cognitive motor dissociation","2026-06-24",{"date":85,"type":48},"2026-06-29",{"date":87,"type":48},"2026-03-16",{"date":89,"type":23},"2029-09",{"name":91,"class":55},"University Hospital, Toulouse",1,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":68,"phases":104,"briefSummary":98,"conditions":105,"keywords":112,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":92},"100633993","functional-outcomes-and-control-using-synchron-bci---australia-100633993","NCT07533903","Functional Outcomes and Control Using Synchron BCI - Australia","Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS)","FOCUS-AUS","Inclusion Criteria:\n\n1. Able to provide informed consent to participate in the study.\n2. Bilateral upper-limb paresis or Amyotrophic lateral sclerosis (ALS) with bilateral upper limb paresis\n3. The underlying condition causing motor impairment must be refractory to treatment and have been present for a minimum of twelve months.\n4. Aged 21 years or older\n5. Life expectancy greater than 12 months post-implantation\n6. Preserved precentral gyrus assessed using CT\n7. Suitable vascular anatomy assessed using CT venography\n8. Suitable anatomy for subcutaneous pocket creation\n9. Able to undergo anesthesia\n10. Willing and able to comply with investigational requirements, including clinical testing visits and training visits in the home.\n11. Caregiver(s) willing and able to facilitate study visits, including visits at the study site and in the home, and BCI use outside of study visits (e.g. device charging)\n12. Patient and caregiver fluent in English\n13. Suitable home environment for BCI training, including an internet connection\n\nExclusion Criteria:\n\n1. Unrealistic expectations regarding the potential benefits of the device.\n2. Active infection or unexplained fever in the 48 hours prior to informed consent\n3. Major psychiatric disorder that may adversely impact the participant's safety or study compliance, including severe depression, psychotic features, personality disorder, severe emotional lability, or substance abuse.\n4. Dementia or cognitive dysfunction that would impact the participant's ability to participate in study activities.\n5. Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).\n6. Known allergy to patient-contacting materials included in the implanted device\n7. Contraindication to angiographic imaging or iodine contrast media.\n8. History of central venous sinus thrombosis.\n9. Recent history of new venous thromboembolic event (in the 6 months prior to implant) or recurrent history of venous thromboembolic disease\n10. Contraindication to antithrombotic therapy.\n11. Participant is at substantially increased risk of infection, including immunocompromised status, recurrent infection, or poorly controlled diabetes mellitus.\n12. Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.\n13. Pregnant or breast feeding.\n14. Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.\n15. Any other disease or disorder that could significantly affect participation in the study. Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.","21 Years",{"count":103,"type":23},10,[70],[35,106,107,108,109,110,111],"Neurologic Diseases","MND (Motor Neurone DIsease)","Motor Neuron Disease","Motor Neuron Disease, Amyotrophic Lateral Sclerosis","Paralysis Arm","Paralysis",[113,114,115,116,117,118],"ALS","BCI","Brain Computer Interface","MND","Upper Limb Paralysis","Motor Neurone Disease","2026-06-05",{"date":121,"type":48},"2026-06-09",{"date":123,"type":48},"2026-05-22",{"date":125,"type":23},"2027-12",{"name":127,"class":128},"Synchron, Inc.","INDUSTRY",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":68,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":92},"100518629","arm-use-with-soft-robotic-glove-100518629","NCT06033027","Arm Use With Soft-robotic Glove","Influence of Assistive Soft-robotic Glove Use on Actual Arm Use in Daily Life","Inclusion Criteria:\n\n* Age between 18 and 90 years\n* Experience difficulties in performing ADL due to hand function limitations as a result of trauma-related injury or neurologic disorder\n* Being in a chronic\u002Fstable phase of disease as judged by their physician\n* Able to activate the soft-robotic glove by generating pressure on finger\u002Fpalm sensors when grasping an object\n* Ability to relax an active grip\n* Sufficient cognitive status to understand two-step instructions\n* Having (corrected to) normal vision\n* Able to provide written informed consent\n* Living independently\n\nExclusion Criteria:\n\n* Severe sensory problems of the most-affected hand\n* Severe acute pain of the most-affected hand\n* Wounds on the hands that can provide a problem when using the glove\n* Severe contractures limiting passive range of motion to the extent that the glove can't be donned\u002Factivated comfortably\n* Co-morbidities limiting functional use\u002Fperformance of the arms and\u002For hands\n* Severe spasticity of the hand (≥2 points on Ashworth Scale)\n* Severe proximal weakness (MRC shoulder elevation\\\u003C4)\n* Used the Carbonhand system in the past 3 months\n* Participation in other studies that can affect functional performance of the arm\u002Fhand\n* Receiving arm-\u002Fhand function therapy during the course of the study\n* Insufficient digital literacy to conduct video calls\n* Insufficient knowledge of the Dutch or English language to understand the purpose or methods of the study","90 Years",{"count":138,"type":23},5,[70],"This study, aimed at investigating the impact of using a supportive soft-robotic glove on actual arm and hand use in daily life, is designed as a single-case experimental design study. 3-5 patients with limitations in hand function due to trauma-related or neurological conditions are asked to participate. Participants will be asked to use a soft-robotic glove at home for six weeks during daily activities relevant to them, while that glove supports the grip of their most affected hand. For several weeks before, during and after the use of the soft-robotic glove, participants will be asked to do some short tests (wearing an activity meter on both wrists during the day, performing a hand squeeze test under the supervision of the researcher via video call) and to answer some questions related to perceived hand function and well-being (a total of at least 15 times during 12-14 weeks). The present study is a follow-up to previous studies that investigated the effect of (previous versions of) the same robotic glove (Carbonhand; Bioservo Technolo-gies AB, Kista, Sweden) on hand function, in order to better understand and explain the observed therapeutic effect.",[142,35],"Trauma Injury of Hand Multiple","2026-05-01",{"date":145,"type":48},"2026-05-07",{"date":147,"type":48},"2024-06-03",{"date":125,"type":23},{"name":150,"class":55},"Roessingh Research and Development",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":92},"100449441","magnesium-and-cognition-after-stroke-100449441","NCT05132517","Magnesium and Cognition After Stroke","Relationship Between Magnesium Concentration in Blood and Kognitive Functions After Stroke","Inclusion Criteria:\n\n* ischemic\u002Fhemmorhagic stroke\n* written consent form\n\nExclusion Criteria:\n\n* pre-existing dementia or cognitive impairment before stroke onset\n* pre-existing mental disorder (depression) or present\u002Fprior long-term treatment (\\> 6 months) with psychotropic drugs\n* pre-existing malign tumor disease\n* participation in another clinical trial within the past 30 days\n* pregnancy or breastfeeding",{"count":159,"type":23},80,"Cognitive impairments such as memory impairments, word-finding difficulties, compromised orientation and perception are often observed in stroke patients.\n\nLow serum-mg-concentrations are associated with cognitive impairments in ischemic stroke patients one month after stroke onset. It is not clear, if cognitive impairments after stroke is caused by the mg-deficiency or by the stroke itself. Until now, no studies investigating the relationship between mg-concentration, stroke severity and cognition during treatment course are available. Thus, this study aimed to investigate the relationship between mg-concentration and cognition of stroke patients.",[162,163,164,35],"Stroke","Cognition","Magnesium","2026-04-16",{"date":167,"type":48},"2026-04-20",{"date":169,"type":48},"2022-10-26",{"date":171,"type":23},"2027-09-30",{"name":173,"class":55},"BDH-Klinik Hessisch Oldendorf",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":68,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100627244","functional-outcomes-and-control-using-synchron-bci---canada-100627244","NCT07446114","Functional Outcomes and Control Using Synchron BCI - Canada","FOCUS-CAN","INCLUSION CRITERIA:\n\n1. Able to provide informed consent to participate in the study, in the opinion of the Investigator(s).\n2. Diagnosis of amyotrophic lateral sclerosis or motor neuron disease, with bilateral upper-limb paresis.\n3. Aged 18 years or older.\n4. Life expectancy greater than 12 months post-implantation, in the opinion of the Investigator(s).\n5. Preserved precentral gyrus assessed using CT.\n6. Suitable vascular anatomy, in the opinion of the Investigator(s), assessed using CT venography.\n7. Suitable anatomy for subcutaneous pocket creation.\n8. Able to undergo anesthesia.\n9. Willing and able to comply with investigational requirements, including clinical testing visits and training visits in the home.\n10. Caregiver(s) willing and able to facilitate study visits, including visits at the study site and in the home, and BCI use outside of study visits (e.g., device charging).\n11. Patient and Caregiver fluent in English.\n12. Suitable home environment for BCI training, including an internet connection.\n\nEXCLUSION CRITERIA:\n\n1. Unrealistic expectations regarding the potential benefits of the device, in the opinion of the Investigator(s).\n2. Active infection or unexplained fever in the 48 hours prior to informed consent.\n3. Major psychiatric disorder that may adversely impact the participant's safety or study compliance (e.g., severe depression, psychotic features, personality disorder, severe emotional lability, substance abuse), in the opinion of the Investigator(s).\n4. Dementia or cognitive dysfunction that would impact the participant's ability to participate in study activities, in the opinion of the Investigator(s).\n5. Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).\n6. Known allergy to patient-contacting materials included in the implanted device (listed in Physician Implant Manual).\n7. Contraindication to angiographic imaging or iodine contrast media.\n8. History of central venous sinus thrombosis.\n9. Recent history of new venous thromboembolic event (in the 6 months prior to implant) or recurrent history of venous thromboembolic disease.\n10. Contraindication to antithrombotic therapy, in the opinion of the Investigator(s).\n11. Participant is at substantially increased risk of infection, including immunocompromised status, recurrent or chronic infection, or poorly controlled diabetes mellitus.\n12. Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.\n13. Currently receiving or expected to require medical treatment that may be precluded by device implant, including magnetic resonance imaging, transcranial magnetic stimulation, electroconvulsive therapy, transcranial ultrasound, shortwave, microwave, and\u002For therapeutic ultrasound diathermy, or balloon angioplasty or stenting in the target vessel.\n14. Pregnant or breast feeding.\n15. Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.\n16. Patients with ALS due to SOD1 mutations on gene therapy.\n17. Any other disease or disorder that could significantly affect participation in the study, in the opinion of the Investigator(s). Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.",{"count":103,"type":23},[70],"Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN)",[35,113,108],[113,114,186,116,108],"Brain computer interface","2026-04-14",{"date":189,"type":48},"2026-04-17",{"date":191,"type":48},"2026-03-18",{"date":193,"type":23},"2027-07",{"name":127,"class":128},2,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":68,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":92},"100512216","does-position-influence-the-diagnosis-of-detrusor-overactivity-in-a-neurological-population-100512216","NCT05949567","Does Position Influence the Diagnosis of Detrusor Overactivity in a Neurological Population","Does Position Influence the Diagnosis of Detrusor Overactivity in a Neurological Population - a Concordance Study Between Lying and Sitting Position","Cysto-position","Inclusion Criteria:\n\n* Patient with MS or neurologically confirmed Parkinson's disease, with indication for urodynamic assessment - 1st assessment\n* Clinical overactive bladder syndrome with USP overactive bladder sub-score \\> or = 4 - Age ≥18 years\n* In men: no prostatic hypertrophy on ultrasonography\n* In women: no stress urinary incontinence (SUI); USP SUI subscore ≤ 2\n* Affiliated with a social security scheme (excluding AME).\n* Free and informed written consent\n\nExclusion Criteria:\n\n* Opposition to the performance of a Urodynamic exam as part of treatment",{"count":205,"type":23},160,[70],"ICS (International Continence Society) recommendations published in 2017 recommend performing urodynamic examinations in the sitting or standing position. These recommendations are based on a review of the literature published in 2008, which has several limitations: heterogeneous populations, old and non-harmonized techniques, and very few neurological patients. It seems appropriate to focus on neurological patients and to examine the influence of position on the detection of detrusor overactivity in these patients.\n\nThe point here is to reexamine the ICS recommendations, which are not designed for neurological patients. Indeed, many patients suffering from Multiple Sclerosis (MS) or Parkinson's disease are unable to sit or stand for the duration of the urodynamic examination. The investigators would like to assess whether exploring sphincter disorders in the supine position is still interpretable.\n\nThis would enable us to define ICS good practice recommendations for a neurological population.",[209,35],"Urodynamic Exam",[211,212,213],"Urodynamic exam","detrusor overactivity","positon",{"date":189,"type":48},{"date":216,"type":48},"2024-04-02",{"date":218,"type":23},"2027-04-02",{"name":220,"class":55},"Assistance Publique - Hôpitaux de Paris",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":68,"phases":230,"briefSummary":231,"conditions":232,"keywords":233,"overallStatus":237,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100633292","the-effect-of-proprioceptive-neuromuscular-facilitation-on-haemodynamic-responses-in-a-neurological-intensive-care-100633292","NCT07524790","The Effect of Proprioceptive Neuromuscular Facilitation on Haemodynamic Responses in a Neurological Intensive Care","The Effect of Proprioceptive Neuromuscular Facilitation on the Ankle-Brachial Index and Haemodynamic Responses in Patients in a Neurological Intensive Care Unit: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Patients being monitored in the neurology intensive care unit\n* Aged 18 years or over\n* Haemodynamically stable\n* No orthopaedic condition preventing the performance of passive joint movements in the upper and lower limbs\n* A signed informed consent form from a patient's next of relative for participation in the study\n\nExclusion Criteria:\n\n* Presence of haemodynamic instability\n* Fractures, contractures or serious orthopaedic conditions in the upper or lower limbs that restrict movement\n* Diagnosis or suspicion of deep vein thrombosis\n* Severe peripheral arterial disease\n* Serious cardiac arrhythmia that may prevent exercise",{"count":229,"type":23},24,[70],"Although there are studies examining the effect of actively performed PNF exercises on haemodynamic responses in intensive care patients and healthy individuals, there are no studies investigating their effect on circulation and haemodynamic responses in unconscious patients. Therefore, this study was designed to investigate the acute effects of proprioceptive neuromuscular facilitation (PNF) exercises on peripheral circulation and haemodynamic responses in patients admitted to a neurological intensive care unit.\n\nHypotheses:\n\nH1-1: Passively administered PNF exercises have beneficial effects on peripheral circulation.\n\nH2-1: Passively administered PNF exercises have beneficial effects on haemodynamic responses.",[35],[234,235,236],"Proprioceptive Neuromusculer Facilitation","Neurological Intensive Care","Haemodynamic Responses","NOT_YET_RECRUITING","2026-04-09",{"date":240,"type":48},"2026-04-13",{"date":242,"type":23},"2026-05-15",{"date":244,"type":23},"2027-05-15",{"name":246,"class":55},"Abant Izzet Baysal University",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":255,"sex":18,"minAge":65,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":68,"phases":258,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":237,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":92},"100543196","early-phase-1-cenobamate-in-the-intensive-care-unit-100543196","NCT06352723","Cenobamate in the Intensive Care Unit","Use of Cenobamate in the Intensive Care Unit for Acute Frequent Seizures and Status Epilepticus","CENOBITE","Inclusion Criteria:\n\n* Age 18-70.\n* Undergoing EEG monitoring.\n* Acute frequent seizures (\\>1\u002Fhour) or status epilepticus (\\>5 min of consecutive seizures, or seizure burden \\>20% within past 1 hour).\n* Adjunctive conventional antiseizure medication indicated.\n\nExclusion Criteria:\n\n* History of medication-related rash.\n* On medication or device affecting enteral absorption (e.g., phenobarbital, pentobarbital).\n* Counterindication to cenobamate as described in the prescribing information.",true,"70 Years",{"count":103,"type":23},[259],"EARLY_PHASE1","The CENOBITE study will be conducted as a multi-center trial involving X leading centers from the Critical Care EEG Monitoring Consortium (CCEMRC). A total of 10 patients will be recruited over a period of one year, with each patient undergoing monitored treatment regimen. Each site will obtain its own approval from their institutional review board. Data will be shared through the MGB REDCap; raw EEG files will be shared through the MGB Dropbox and analyzed at the BWH.\n\nMonitoring for the development of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, a potential adverse reaction, will be a key aspect of the study. Regular assessments, including RegiSCAR scoring (a validated scoring system for DREeSS5), daily serum cenobamate level measurements, and comprehensive lab tests, will be conducted to ensure patient safety and the effective management of any adverse reactions such as DRESS syndrome.",[262,35],"Epilepsy",[264],"ICU","2026-03-25",{"date":267,"type":48},"2026-03-30",{"date":269,"type":23},"2026-06",{"date":271,"type":23},"2029-06",{"name":273,"class":55},"Brigham and Women's Hospital",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":65,"enrollmentInfo":282,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":284,"conditions":285,"keywords":294,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":92},"100561089","a-multicenter-pediatric-deep-brain-stimulation-registry-100561089","NCT06585618","A Multicenter Pediatric Deep Brain Stimulation Registry","Multicenter Pediatric Deep Brain Stimulation Registry","DBS-R","Inclusion Criteria:\n\n* Female or male patients between ages of 0-18 years.\n* Having received or scheduled to receive DBS for any neurological movement disorder.\n* Parents or legal guardians are able to provide written consent for prospective enrollment.",{"count":283,"type":23},100,"There is limited data on outcomes for children who have undergone deep brain stimulation (DBS) for movement disorders, and individual centers performing this surgery often lack sufficient cases to power research studies adequately. This study aims to develop a multicenter pediatric DBS registry that allows multiple sites to share clinical pediatric DBS data. The primary goals are to enable large-scale, well-powered analyses of the safety and efficacy of DBS in the pediatric population and to further explore and refine DBS as a therapeutic option for children with dystonia and other hyperkinetic movement disorders. Given the current scarcity of evidence available to clinicians, this centralized multicenter repository of clinical data is critical for addressing key research questions and improving clinical practice for pediatric DBS.",[286,287,288,289,290,35,291,292,293],"Dystonia","Epilepsy in Children","Cerebral Palsy","Tourette Syndrome","Obsessive-Compulsive Disorder","Movement Disorders in Children","Movement Disorders","Deep Brain Stimulation",[293,295,296,297,298,299,300,301],"DBS","movement disorder","movement disorders in children","dystonia","chorea","dyskinesia","epilepsy",{"date":191,"type":48},{"date":304,"type":48},"2024-07-30",{"date":306,"type":23},"2029-07-30",{"name":308,"class":55},"Boston Children's Hospital",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":65,"enrollmentInfo":315,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":317,"conditions":318,"keywords":324,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":92},"100561088","a-retrospective-survey-based-multicenter-study-to-delineate-the-molecular-and-phenotypic-spectrum-of-epilepsy-dyskinesia-syndromes-100561088","NCT06585605","A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes","Inclusion Criteria:\n\n* Children between 0 - 18 years of age with a movement disorder and a pathogenic or likely pathogenic variant in one of the genes of interest:\n\nAARS2 ALG13 AP3B2 AP4B1 AP4E1 AP4M1 AP4S1 ARX ATP1A3 CACNA1A CACNA1E CACNA2D2 CDKL5 CSTB DARS2 DLAT DLD DNM1 EARS2 EPG5 FARS2 FOXG1 FRRS1L GABRA1 GABRA2 GABRB2 GABRB3 GABRG2 GRIA2 GRIA4 GRIN1 GRIN2A GRIN2B GRIN2D GNAO1 HARS2 HNRNPU IQSEC2 KCNA2 KCNB1 KCNC1 KCNMA1 KCNQ2 KCNQ3 KCNT1 LARS2 MECP2 MEF2C MTND5 MTTL1 MTTK NARS2 NHLRC1 PDE10A PDE2 PCDH12 PCDH19 PDK3 PIGP PIGQ PIGS PIGN POLG PDHA1 PDHB PDHX PRRT2 PURA RHOBTB2 SCN1A SCN1B SCN2A SCN8A SCN9A SLC13A5 SLC1A2 SLC2A1 SLC25A22 SMCA1 SNP14 ST3GAL3 STXBP1 SPTAN1 SYNGAP1 TBC1D24 TBL1WL1 TARS2 UBA5 UBE3A VAMP2 VARS2 WARS2 WDOX WDR45 YIF1B YWHAG\n\nExclusion Criteria:\n\n* Not having such diagnosis and\u002For not presenting a movement disorder.",{"count":316,"type":23},500,"The Epilepsy-Dyskinesia Study aims to advance the understanding of the clinical and molecular spectrum of epilepsy-dyskinesia syndromes, monogenic diseases that cause both movement disorders and epilepsy. Addressing challenges in rare disease research -such as small, geographically dispersed patient populations and a lack of standardized protocols- the study employs a multinational retrospective survey endorsed by the International Parkinson and Movement Disorder Society. This survey seeks to collect comprehensive data on clinical features, disease progression, age of onset, genetic variants, and concurrent neurological conditions, standardizing data collection across countries to provide a unified understanding of these conditions. Through retrospective review and molecular data analysis, the study aims to identify patterns and correlations between movement and seizure disorders, uncovering genotype-phenotype relationships. The initiative\\'s goals are to enhance understanding of epilepsy-dyskinesia syndromes, inform precision medicine approaches, and foster international collaboration.",[287,319,291,35,320,321,322,262,323,292],"Dyskinesias","Chorea","Myoclonus","Ataxia","Dystonia Disorder",[325,326,327,300,298,328,329,330,40,331,332,333,334,335,336,337,338,339],"epilepsy-dyskinesia syndrome","movement disorders","epileptic encephalopathy","neurogenetics","PRRT2","ATP1A3","CACNA1A","CDKL5","FOXG1","GNAO1","SCN1A","SCN8A","SLC2A1","STXBP1","UBA5",{"date":191,"type":48},{"date":342,"type":48},"2024-07-01",{"date":344,"type":23},"2029-12-31",{"name":308,"class":55},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":18,"minAge":353,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":68,"phases":357,"briefSummary":358,"conditions":359,"keywords":363,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":92},"100573777","comparison-of-the-effects-of-mirror-therapyrtms-and-robotic-assisted-hand-therapy-in-stroke-patients-100573777","NCT06750692","Comparison of the Effects of Mirror Therapy,rTMS and Robotic-assisted Hand Therapy in Stroke Patients","Comparison of the Effects of Mirror Therapy,Repetitive Transcranial Magnetic Stimulation and Robotic-assisted Hand Therapy Added to Neurological Rehabilitation on Upper Extremity Functions, Quality of Life and Pain in Stroke Patients","Inclusion Criteria:\n\n* Patients who applied to Afyonkarahisar Health Sciences University Hospital Physical Medicine and Rehabilitation Polyclinic with the diagnosis of hemiplegia after a cerebrovascular accident in the inpatient ward or as an outpatient for neurological rehabilitation after taking the anamnesis and physical examination, who met the inclusion criteria and eliminated the exclusion criteria\n* Female and male patients between the ages of 40-80\n* stroke at least 3 months ago\n* voluntarily agreed to participate in the study regularly, whose health status is suitable for rehabilitation and who are medically stable\n* mini mental test score of 15 and above\n* Neurologically stable patient\n\nExclusion Criteria:\n\n* significant comorbidities such as serious heart disease (aortic stenosis, angina, hypertrophic cardiomyopathy, arrhythmia, pacemaker) and uncontrolled hypertension\n* history of epilepsy, antiepileptic drug use\n* intracranial metal objects\n* intraauricular implants\n* cognitive dysfunction\n* upper extremity peripheral nerve injuries\n* malignancy\n* active infection\n* skin infections or open wounds in the application area\n* inflammatory diseases\n* orthopedic injuries that may limit maximum effort capacity\n* brain lesion or drug use history that may affect the seizure threshold\n* increased intracranial pressure\n* uncontrolled migraine\n* severe spasticity in the hand (MAS≥3)\n* contracture in the hand\n* have had a fracture or surgery on the hemiplegic side in the last 6 months\n* severe visual impairment\n* severe depression","40 Years","80 Years",{"count":356,"type":23},120,[70],"The aim of the study is to investigate the comparison of the effects of mirror therapy, Repetitive Transcranial Magnetic Stimulation and robot-assisted hand therapy added to conventional neurological rehabilitation on upper extremity function, quality of life and pain in stroke.",[162,360,361,362,35],"Upper Extremity Dysfunction","Neuropathic Pain","Quality of Life",[364,365,366],"Mirror Therapy","Repetitive Transcranial Magnetic Stimulation","Hand-Finger Robot","2026-03-11",{"date":369,"type":48},"2026-03-12",{"date":371,"type":48},"2024-12-27",{"date":373,"type":23},"2026-06-20",{"name":375,"class":55},"Afyonkarahisar Health Sciences University",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":383,"maxAge":4,"enrollmentInfo":384,"targetDuration":386,"studyType":25,"phases":4,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":92},"100508502","the-exopulse-study---a-database-for-routine-follow-up-of-clinical-outcomes-100508502","NCT05901259","The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes","EXOREG","Inclusion Criteria:\n\n* Diagnosed with CP, MS, stroke, fibromyalgia or other neurologic disorder that may cause such type of symptoms.\n* Diagnosed \\>6 months prior to inclusion in case of MS or stroke as well as \\>1 month prior to inclusion in the case of fibromyalgia.\n* Give written informed consent\n* Cognitively able to understand and follow verbal and\u002For written instructions\n* A minimum age of 2 years\n\nExclusion Criteria:\n\n* Any of the contraindications listed in the instructions for use of the EXOPULSE Mollii Suit or EXOPULSE Suit\n* Being introduced to any new medication affecting the neuromuscular activity during the study period\n* Using botulinum toxin \\\u003C3 month before or during the study period\n* Subjects \\\u003C100 cm and \\\u003C13 kg\n* Subjects \\>205 cm and \\>115 kg","2 Years",{"count":385,"type":23},200,"4 Weeks","The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg\u002FPediatric Balance Scale (BBS\u002FPBS) as a measurement of balance and risk of falls.",[288,389,162,35,390],"Multiple Sclerosis","Fibromyalgia",[381],"2026-02-26",{"date":394,"type":48},"2026-02-27",{"date":396,"type":48},"2026-02-18",{"date":398,"type":23},"2027-12-31",{"name":400,"class":128},"Exoneural Network AB",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":407,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":68,"phases":409,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":423,"locationsCount":92},"100532094","phase-2-the-what-is-important-to-us-communication-intervention-pilot-clinical-trial-100532094","NCT06208332","The \"What Is Important to Us\" Communication Intervention Pilot Clinical Trial","Children with SNI\n\nInclusion\n\n* Hospitalized at study sites\n* Ages 6 months through 25 years old\n* Has had SNI for \\>6 months, defined as permanent static or progressive central nervous system injury resulting in motor\u002Fcognitive impairment and medical complexity\n\nExclusion\n\n* Has never previously been home\u002Fdischarged\n* Has an expected hospital length of stay \\\u003C2 days\n* Has a life expectancy of \\\u003C4 weeks\n* Previous study participation\n\nParents\n\nInclusion\n\n* Parent\u002Flegally authorized representative of an eligible child with SNI\n* Preferred language of care English and\u002For Spanish\n\nClinicians\n\nInclusion -Licensed physicians, nurses, advanced practice providers, respiratory therapists at study site\n\nExclusion\n\n-Previous study participation","6 Months",{"count":205,"type":23},[410],"PHASE2","The objective of this study is to conduct a pilot randomized controlled trial (RCT) of a photo-narrative communication intervention developed by our study team with patients\u002Fparents of children with severe neurological impairment (SNI) and their pediatric intensive care unit (PICU) clinicians to assess feasibility, acceptability, and early efficacy.",[413,35],"Critical Illness",[415,416,417],"pediatric palliative care","communication","severe neurological impairment","2026-02-12",{"date":396,"type":48},{"date":421,"type":48},"2025-02-10",{"date":244,"type":23},{"name":424,"class":55},"Seattle Children's Hospital",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":92},"100556297","advanced-imaging-holistic-omics-biobank-100556297","NCT06523270","Advanced Imaging Holistic Omics Biobank","Inclusion Criteria:\n\n* Adult subjects (\\>18 y.o.) submitted to Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI) exams acquired with 3T scanner (MR 7700, Philips) for examination required for clinical practice or for clinical trials at the IRCCS San Raffaele Hospital who signe an Informed Consent authorizing data collection.\n\nExclusion Criteria:\n\n* Absent informed consent signed",{"count":432,"type":23},50000,"Imaging methods today represent the pillar of prevention, diagnosis, patients monitoring and treatment. Improvement in technology led the development of increasingly high-performance scanners whose potential has not yet been fully explored. In particular, recently introduced photon counting CT scanner and new high filed MRI offers a lake of latent information derived from the images (e.g. spectral data from CT) of potentially great interest and potentially able to provide new insight but that are currently mostly unexplored .These features are also called \"opportunist features\" because they are in each exam and can be freely derived from images without changing the study protocol used for clinical practice examination but extracted a posteriori from the images representing a precious source of deep characterization of the patients, equally or even more than a genomic analysis, with possible high relevance in the field of screening and prevention, being able to contribute to defining signatures indicating a particular risk of remotely developing a specific pathological condition. The prospective collection of clinical and imaging data from subjects undergoing diagnostic tests with advanced technology has the potential to increase knowledge of the pathophysiological mechanisms of different pathological conditions, to explore and validate the diagnostic-predictive value of opportunistic features not currently used in practice clinical, to increase the diagnostic and prognostic accuracy of CT and MRI examinations and to provide a unique pool for scientific research. Previous relevant experience was conducted in the United Kingdom (UK biobank) where data from over 500,000 patients have been collected in the last 10 years, providing an enormous pool for spontaneous and funded scientific research. This project (UK biobank), although of enormous scientific value, is currently obsolete in terms of the imaging technology used.",[435,35,436,437],"Oncologic Disorders","Pulmonary Disease","Cardiovascular Diseases","2026-01-14",{"date":440,"type":48},"2026-01-15",{"date":442,"type":48},"2024-09-15",{"date":444,"type":23},"2034-09-15",{"name":446,"class":55},"IRCCS San Raffaele",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":68,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":237,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":4},"100619336","ask-questions-about-clinical-trials-100619336","NCT07343297","Ask Questions About Clinical Trials","Ask Questions About Clinical Trials (ASQ - CT): An Implementation Trial of a Communication Intervention to Improve Patient-Provider Communication About Clinical Trials and Provider Invitations to Clinical Trials","ASQ-CT","Inclusion Criteria:\n\n* Age \\> or equal to 18 years\n* Appointment to see a provider at a Karmanos Cancer Institute-McLaren or a medical encounter at McLaren Center for Research and Innovation (MCRI) site for medical\u002Fsystemic treatment\n* Potentially eligible for a clinical trial\n* Speak and read English well enough to be able to understand consent documents and complete surveys\n\nExclusion Criteria:\n\n* Not able to complete study documents on their own physically or cognitively",{"count":456,"type":23},293,[70],"The overall goal of this study is to assess the implementation of the Ask Questions about Clinical Trials (ASQ-CT) brochure, a patient-focused communication tool previously demonstrated to improve patient-provider communication about clinical trials. Participants will be given the ASQ-CT brochure at Time 1 (baseline) and participants will complete a questionnaire at three timepoints, baseline (Time 1), Pre-Research Visit (Time 2), and Post-Research Visit (Time 3).",[460,461,35],"Oncology","Cardiac Disease","2026-01-06",{"date":440,"type":48},{"date":465,"type":23},"2026-04-30",{"date":467,"type":23},"2027-04-05",{"name":469,"class":55},"Barbara Ann Karmanos Cancer Institute",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":479,"conditions":480,"keywords":482,"overallStatus":237,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":92},"100617013","longitudinal-assessment-of-protein-markers-in-the-cerebrospinal-fluid-of-patients-with-central-nervous-system-involvement-100617013","NCT07313098","Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement","HJ-COLOCS","Inclusion Criteria:\n\n1. Patients with a neurological condition diagnosed by a physician requiring cerebrospinal fluid (CSF) collection, through:\n\n   * Neurosurgical procedure (EVD, VP shunt, VSG shunt, tumor surgery, spinal surgery with dural opening, ELD);\n   * Lumbar puncture (LP).\n2. Patients who have (or whose legal guardians, where applicable, have) consented to the storage and reuse of residual biological samples collected during the course of care within the biological collection.\n\nExclusion Criteria:\n\n1\\. Objection by the patient and\u002For the legal guardian, if the patient is a minor, to participation in the study.",{"count":478,"type":23},1000,"In the context of adult pathology, research into biomarkers in cerebrospinal fluid (CSF) has already identified proteins that are commonly used for the early diagnosis of certain neurodegenerative diseases. However, the lack of data available in the literature on pediatric diseases has limited the use of biomarkers in routine practice in children. Importantly, our group has pioneered the establishment of CSF biomarkers in children (e.g., measurement of interferon alpha in CSF by ultra-sensitive digital ELISA), which will undoubtedly be used in routine clinical practice in the future. In light of these arguments, the establishment of a CSF biobank will have major clinical implications, given the rarity of the diseases treated and the number of patients followed.",[35,481],"Central Nervous System Diseases",[483,481,35],"Cerebrospinal Fluid","2025-12-22",{"date":486,"type":48},"2025-12-31",{"date":488,"type":23},"2026-03-01",{"date":490,"type":23},"2036-01-01",{"name":492,"class":55},"Imagine Institute",{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":500,"maxAge":65,"enrollmentInfo":501,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":195},"100616404","a-multicenter-retrospective-analysis-of-postoperative-respiratory-complications-in-children-with-obstructive-sleepapnea-100616404","NCT07305168","A Multicenter Retrospective Analysis of Postoperative Respiratory Complications in Children With Obstructive Sleepapnea","MRA PORC","Inclusion Criteria:\n\n* scheduled for (adeno)tonsillectomy as treatment for OSAS\n\nExclusion Criteria:\n\n* other surgery than (adeno)tonsillectomy performed as treatment for OSAS\n* Polysomnography not available within 1 year before surgery","1 Year",{"count":385,"type":23},"This retrospective observational study aims to evaluate postoperative respiratory complications (PORC) after (adeno)tonsillectomy in children with OSA.\n\nIn order to increase the number of patients available for analysis, we will merge data collected at UZA with data collected at the the Department of Sleep Laboratory and Sleep Surgery at the Heim Pal National Pediatric Institute, Hungary. These colleagues performed an identical prospective data collection.",[504,505,506,507,508,509,35],"Obstructive Sleep Apnea","Postoperative Respiratory Complications","Adenotonsillectomy","Child Obesity","Craniofacial Abnormalities","Children With Down Syndrome","2025-12-11",{"date":512,"type":48},"2025-12-26",{"date":514,"type":48},"2022-05-02",{"date":516,"type":23},"2027-03-01",{"name":518,"class":55},"University Hospital, Antwerp",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":529,"conditions":530,"keywords":533,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":92},"100396710","prognostic-factors-to-regain-consciousness-100396710","NCT04445649","Prognostic Factors to Regain Consciousness","Investigation of Prognostic Factors to Regain Consciousness in Neurological Early Rehabilitation","Inclusion Criteria:\n\n* early neurological rehabilitation (phase B)\n* stroke, traumatic brain injury, hypoxic-ischemic encephalopathy\n* disorder of consciousness (coma, UWS, MCS)\n* at minimum two weeks after disease onset\n* admission to intensive care unit\n* written consent from the patient's legal representative\n* exclusion of pregnancy\n\nExclusion Criteria:\n\n* insufficient cardiorespiratory stability\n* fractures or severe infratentorial brain injuries leading to impaired auditory evoked - potentials\n* previous brain damage\n* mental disorders (dementia, depression)\n* colonization with multi-resistant pathogens\n* MRI contraindications\n* claustrophobia\n* weight \\> 120 kg","85 Years",{"count":528,"type":23},130,"The study aims to identify factors that predict the medium and long-term outcome of patients with disorders of consciousness (DOC) undergoing early neurological rehabilitation.\n\nIn this prospective, observational study, 130 DOC patients are going to be included (36 months). At study entry, different routine data, disease severity and functional status are documented for each patient. In addition, MRI, EEG and evoked potentials are measured within the first week. The level of consciousness is recorded with the Coma-Recovery-Scale-Revised and serves as the primary outcome parameter. Complications, comorbidities, functional status and leve of consciousness are assessed weekly. After eight weeks, the measurement of the MRI, the EEG and the evoked potentials are repeated. After 3, 6 and 12 months, the Glasgow Outcome Scale-Revised is used to followed up the current status of the patients.",[35,75,531,162,532],"Traumatic Brain Injury","Hypoxic-Ischemic Encephalopathy",[534,535,536,537],"Neurological rehabilitation","Prognosis","Outcome","Level of consciousness","2025-09-18",{"date":540,"type":48},"2025-09-19",{"date":542,"type":48},"2020-06-15",{"date":544,"type":23},"2027-12-15",{"name":173,"class":55},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":526,"enrollmentInfo":553,"targetDuration":4,"studyType":68,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":563,"startDateStruct":564,"completionDateStruct":565,"leadSponsor":567,"locationsCount":92},"100396505","effectiveness-of-music-therapy-on-level-of-consciousness-100396505","NCT04442971","Effectiveness of Music Therapy on Level of Consciousness","Investigation of the Effectiveness of Music Therapy on the Level of Consciousness of Neurological Early Rehabilitation Patients","Inclusion Criteria:\n\n* early neurological rehabilitation (phase B)\n* traumatic brain injury\n* disorder of consciousness (coma, UWS, MCS)\n* at minimum two weeks after disease onset\n* admission to intensive care unit\n* written consent from the patient's legal representative\n* Exclusion of pregnancy\n\nExclusion Criteria:\n\n* insufficient cardiorespiratory stability\n* fractures or severe infratentorial brain injuries leading to impaired auditory evoked potentials\n* previous brain damage\n* Known mental disorders (dementia, depression)\n* hearing loss or deafness in one or two ears\n* wounds that do not allow you to wear headphones\n* colonization with multi-resistant pathogens\n* MRI contraindications\n* claustrophobia\n* weight\\>120 kg",{"count":554,"type":23},66,[70],"It is known that even in patients with severe disorders of consciousness (DOC), the perception of known stimuli triggers emotional reactions that can be interpreted as an expression of a residual function of consciousness. Music therapy has a long tradition in neurological rehabilitation. Frequently, active therapies with own music making and singing are implemented in clinical settings. In DOC patients, it is more likely to use passive music listening. However, findings on effectiveness are limited, as only a few studies have systematically investigated the effects of music therapy in this population. Therefore, the investigators want to investigate the effectiveness of passive listening to preferred music on the level of consciousness.",[35,531,75],[559,560,561,562],"neurological rehabilitation","music therapy","level of consciousness","default mode network",{"date":540,"type":48},{"date":542,"type":48},{"date":566,"type":23},"2026-12-15",{"name":173,"class":55},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":256,"enrollmentInfo":575,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":577,"conditions":578,"keywords":580,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":586,"locationsCount":92},"100397018","hippocampal-volume-and-memory-functions-in-aneurysmal-subarachnoid-hemorrhage-100397018","NCT04449666","Hippocampal Volume and Memory Functions in Aneurysmal Subarachnoid Hemorrhage","Investigation of the Relationship Between Hippocampal Volume and Memory Functions in in Patients With Aneurysmal Subarachnoid Hemorrhage (aSAH)","Inclusion Criteria:\n\n* neurological rehabilitation patients in phase B - D\n* at minimum eight weeks after disease onset\n* aneurysmal subarachnoid hemorrhage (Hunt \\& Hess grade I or II)\n* written consent from the patient's legal representative\n* exclusion of pregnancy\n\nExclusion Criteria:\n\n* insufficient cardiorespiratory stability\n* previous brain damage\n* mental disorders (dementia, depression)\n* colonization with multi-resistant pathogens\n* MRI contraindications\n* claustrophobia\n* weight \\> 120 kg",{"count":576,"type":23},30,"Neuropsychological and functional long-term consequences of subarachnoid hemorrhages (SAH) represent a great challenge, since sometimes considerable cognitive deficits occur without evidence of substantial brain damage. In this study, we want to examine if the frequently observed memory deficits are associated with hippocampal atrophy.",[35,579],"Subarachnoid Hemorrhage, Aneurysmal",[534,581,582],"Hippocampal volume","Memory deficits",{"date":540,"type":48},{"date":542,"type":48},{"date":566,"type":23},{"name":173,"class":55},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":593,"enrollmentInfo":594,"targetDuration":4,"studyType":68,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":92},"100603150","evaluation-of-the-safety-and-efficacy-of-a-full-body-electrostimulation-garment-for-individuals-with-neurological-and-neuromuscular-conditions-that-cause-spasticity-hyperreflexia-and-pain-100603150","NCT07132775","Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain","Inclusion Criteria:\n\n1. Age 18 to 75 years old\n2. Medical clearance from physician\n3. Individuals who experience spasticity, pain, or hyperreflexia due to neurological or neuromuscular conditions or individuals with a diagnosis of Multiple Sclerosis or Fibromyalgia\n4. For participants with a diagnosis of Multiple Sclerosis:\n\n   1. having a definite diagnosis for at least one month\n   2. Ability to walk independently or with the need of support (expanded disability status scale score (EDSS) \\\u003C 7).\n   3. Absence of relapses in the last three months\n   4. Demonstrating spasticity with a score of at least 1+ on the Modified Ashworth Scale (MAS)\n   5. Berg Balance Scale (BBS) score of \\\u003C 46 (associated in the literature with a risk of fall)\n5. For participants with a diagnosis of Fibromyalgia:\n\n   a. having a definite diagnosis for at least three months\n6. Able to follow instructions and inform study staff of pain and\u002For discomfort\n7. Able to ambulate 10m without body weight support with or without assistive devices and\u002For caregiver assistance\n\nExclusion Criteria:\n\n1. Implanted medical devices or equipment which can be disrupted by magnets (ex. Shunts)\n2. Swollen, infected, or inflamed areas or skin eruptions (e.g., phlebitis, thrombophlebitis, varicose veins, etc.) in areas where the suit will be used\n3. No established somatic or neuropsychiatric diagnosis prior to enrollment in the study\n4. Pregnant and\u002For nursing","75 Years",{"count":595,"type":23},15,[70],"The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity, hyperreflexia, and\u002For pain.",[389,390,35,599],"Neuromuscular Disorders","2025-09-02",{"date":602,"type":48},"2025-09-09",{"date":604,"type":48},"2025-07-23",{"date":193,"type":23},{"name":607,"class":55},"Shirley Ryan AbilityLab",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":614,"enrollmentInfo":615,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":617,"conditions":618,"keywords":623,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":92},"100590462","registry-and-natural-history-of-epilepsy-dyskinesia-syndromes-100590462","NCT06967727","Registry and Natural History of Epilepsy-Dyskinesia Syndromes","Inclusion Criteria:\n\n* Having at least one pathogenic or likely pathogenic variant in one of the genes of interest:\n\nAARS2, ADCY5, ALG13, AP3B2, AP4B1, AP4E1, AP4M1, AP4S1, ARX, ATP1A3, CACNA1A, CACNA1E, CACNA2D2, CDKL5, CSTB, DARS2, DLAT, DLD, DNM1, EARS2, EPG5, EPM2A, FARS2, FOXG1, FRRS1L, GABRA1, GABRA2, GABRB2, GABRB3, GABRG2, GNAO1, GRIA2, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2D, HARS2, HNRNPU, HTT, IQSEC2, IRF2BPL, KCNA2, KCNB1, KCNC1, KCNMA1, KCNQ2, KCNQ3, KCNT1, LARS2, MECP2, MEF2C, MTND5, MTTK, MTTL1, NARS2, NHLRC1, PCDH12, PCDH19, PDE10A, PDE2, PDHA1, PDHB, PDHX, PDK3, PDP1, PIGA, PIGN, PIGP, PIGQ, PIGS, PLCB1, POLG, PRRT2, PURA, RHOBTB2, SCN1A, SCN1B, SCN2A, SCN8A, SCN9A, SETBP1, SETD5, SLC13A5, SLC1A2, SLC25A22, SLC2A1, SMC1A, SNX14, SPTAN1, ST3GAL3, STXBP1, SYNGAP1, SYNJ1, SZT2, TARS2, TBC1D24, UBA5, UBE3A, VAMP2, VARS2, WARS2, WDR45, WWOX, YIF1B, YWHAG, and other genes associated with epilepsy-dyskinesia syndromes.\n\nExclusion Criteria:\n\n* Not having a pathogenic or likely pathogenic variants in the genes of interest","30 Years",{"count":616,"type":23},700,"The Registry and Natural History of Epilepsy-Dyskinesia Syndromes is focused on gathering longitudinal clinical data as well as biological samples (blood, urine, and\u002For skin\u002Ftissue) from male and female patients, of all ages, who have a genetic diagnosis of epilepsy-dyskinesia syndromes. Through prospective review and molecular data analysis, the study aims to identify patterns and correlations between movement and seizure disorders, uncovering genotype-phenotype relationships. The initiative's goals are to enhance understanding of epilepsy-dyskinesia syndromes, inform precision medicine approaches, and foster international collaboration.",[619,262,620,621,622,287,319,291,35,320,321,322,323,292],"Epilepsy-Dyskinesia","Dyskinesia","EDS","Epilepsy-Dyskinesia Syndomes",[301,619,624,620,326,327,328,329,330,334,40,331,332,333,335,336,337,338,339,625],"Epilepsy-Dyskinesia Syndrome","ADCY5","2025-08-15",{"date":628,"type":48},"2025-08-17",{"date":630,"type":48},"2025-06-01",{"date":632,"type":23},"2030-07",{"name":308,"class":55},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":18,"minAge":65,"maxAge":593,"enrollmentInfo":642,"targetDuration":4,"studyType":68,"phases":643,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":92},"100534259","effect-of-transcranial-direct-current-stimulation-in-altered-states-of-consciousness-100534259","NCT06236503","Effect of Transcranial Direct Current Stimulation in Altered States of Consciousness","Effect of Daily Transcranial Direct Current Stimulation on the Cognitive Evolution of Patients in an Altered State of Consciousness","tDCS-GCA","Inclusion Criteria:\n\n* Patients diagnosed with a minimally conscious state will be evaluated and stimulated, provided that written informed consent is obtained from a family member.\n\nExclusion Criteria:\n\npatients in coma patients with metallic brain implants, craniotomy or pacemaker",{"count":283,"type":23},[70],"Transcranial Direct Current Stimulation (tDCS) is a non-invasive, painless brain stimulation treatment that uses low-intensity direct electrical currents to stimulate specific parts of the brain. Transcranial Direct Current Stimulation (tDCS) can both facilitate anodic stimulation and inhibit cathodic stimulation specific brain areas since many neurological and psychiatric disorders are connected to hypoactivity or hyperactivity in specific areas of the nervous system. This phenomenon is based on two processes: the reorganization of functional neural circuits and their reconstruction. In light of the studies mentioned above, it is presumed that Transcranial Direct Current Stimulation (tDCS) can be a valuable tool to facilitate the process of neuroplasticity in individuals with chronic neurological diseases and in patients with impaired consciousness following severe brain injury. A previous study demonstrated that a single session of transcranial direct current electrical stimulation could temporarily improve signs of consciousness in patients in a minimally conscious state (MCS)",[35,646],"Brain Injuries","2025-04-29",{"date":649,"type":48},"2025-05-01",{"date":651,"type":48},"2023-01-10",{"date":653,"type":23},"2025-12-30",{"name":655,"class":55},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":255,"sex":18,"minAge":65,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":666,"conditions":667,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":92},"100532413","an-observational-study-on-theaccuracy-of-whole-body-magnetic-resonance-imaging-wb-mri-screeningto-predict-clinically-significant-diagnoses-in-general-population-subjects-interested-in-proactive-and-advanced-general-preventive-healthcare-100532413","NCT06212479","An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.","A Multi-Site Prospective, Single-Arm, Observational Study On The Accuracy Of Whole Body Magnetic Resonance Imaging (Wb-Mri) Screening To Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.","Hercules","Inclusion Criteria:\n\n* Each subject MUST:\n\n  * Be\\>=18 years of age at the time of enrollment.\n  * Be able to read and understand provided procedural information for the study;\n  * Be able and willing to follow all study procedures including proper breathing and body movement minimization while within the WB-MRI system;\n  * Be willing and able to provide required clinical, demographic, medical history, and concomitant medications information;\n  * Be able to provide financial payment in advance for reimbursement of the cost of the WBMRI acquisition procedure and interpretation;\n  * Complete all required consent procedures.\n\nExclusion Criteria:\n\n* Harbor within their bodies contraindicated medical devices including, but not limited to, implanted pacemakers, intracranial aneurysm clips, cochlear implants, drug infusion pumps, neurostimulators, bone growth stimulators, certain intrauterine contraceptive devices, non- MRI safe metals, etc.;\n\n  * Self-certify that they are pregnant;\n  * Be seeking to undergo WB-MRI as a subject in this study in lieu of other covered dedicated diagnostic imaging evaluations when such covered procedures represent more appropriate or standard-of-care procedures by context-specific clinical indication;\n  * Be an employee of the study site or the sponsor;\n  * Have a medical condition or serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the candidate's safety as a study subject, or that could interfere with study objectives.",{"count":665,"type":23},100000,"This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion and exclusion criteria. Potential subjects arriving at the study sites will be evaluated for enrollment. It is the Principal Investigator's (PI) responsibility to enroll only subjects who satisfy the inclusion\u002Fexclusion criteria. Recruitment can occur by subject presentation at the sites for elective standard screening, word-of-mouth, flyers, healthcare professional (HCP) referrals, advertisement online, or any other means, subject to approval by the associated institutional review board (IRB) or ethics committee (EC) when applicable.",[668,669,670,35],"Cancer","Metabolic Disease","Aneurysm","2025-04-28",{"date":673,"type":48},"2025-04-30",{"date":675,"type":48},"2024-05-17",{"date":677,"type":23},"2037-01",{"name":662,"class":128}]